

writes, "The overall effect . . . was that the patients felt an increase in well-being and marital happiness. The effects were not limited to the wives. Many husbands expressed their satisfaction with the method and none wished to return to methods formerly used." Mears, too, thinks¹⁹ that much more prominence should be given to the positive effects mentioned by patients: "Many patients have expressed themselves as being absolutely delighted with the freedom from contraceptive measures related to coital acts, of being more confident and relaxed at intercourse . . . feeling better than ever before. . . ." Physicians as well as their patients, it is stated⁴⁰ in the *British Medical Journal*, "find great relief in the freedom from anxiety which this method [oral contraception] offers."

These psychologic aspects of oral contraception are no doubt largely responsible for the fact that ENOVID-E and ENOVID have attained a remarkable acceptance and rapid popularity² "no matter what the intellectual or social status of the women may be." Commenting on the ac-

ceptance of the oral method, it is stated⁴⁰ in the *British Medical Journal*: "Though it was at first expected that this method would be suitable only for intelligent conscientious women, this is not so. It has been found that many feckless women who have been quite inconsistent over other contraceptive measures have found this method highly acceptable and have never missed a tablet."

Summary: The significance of Enovid-E. Clinical experience — the longest experience behind any low-dosage oral contraceptive — makes it clear that ENOVID-E enjoys outstanding acceptance, psychologically as well as physically, and that its effects, like those of ENOVID, are fully reversible when cyclic use is terminated.

Acceptance is further enhanced by a very significant practical consequence of the low ENOVID-E dosage: economy. Women may now have the benefits of fully effective oral control of fertility at far less expense.

References

- Goldzieher, J. W.: Newer Drugs in Oral Contraception, *Med. Clin. N. Amer.* 48:529-545 (March) 1964.
- García, C.-R., and Pincus, G.: Hormonal Inhibition of Ovulation, in Calderone, M. S. (editor): *Manual of Contraceptive Practice*, Baltimore, The Williams & Wilkins Company, 1964, pp. 206-221.
- Swyer, G. I. M.: Notes and Queries: Oral Contraceptives, *Practitioner* 190:155-156 (Jan.) 1963.
- Roland, M.; Clyman, M. J.; Decker, A., and Ober, W. B.: Classification of Endometrial Response to Synthetic Progestogen-Estrogen Compounds, *Fertil. Steril.* 15:143-163 (March-April) 1964.
- García, C.-R.; Rock, J., and Pincus, G.: Proceedings of a Symposium on Enovid: Observations on Prolonged Administration of Enovid, Chicago, Searle Research Laboratories, 1959, pp. 35-41.
- Rice-Wray, E.: Proceedings of a Symposium on 19-Nor Progestational Steroids: Field Study with Enovid as a Contraceptive Agent, Chicago, Searle Research Laboratories, 1957, pp. 78-85.
- Eckstein, F., and others: The Birmingham Oral Contraceptive Trial, *Brit. J. Med.* 2:1172-1179 (Nov. 4) 1961.
- Wiseman, A.: Investigator's Clinical Report, April 15, 1963; this is a continuation of the published report, Reference No. 19.
- Binks, R.; Cambourn, P., and Papworth, R. A.: Preliminary Report of a Clinical Trial of Oral Norethynodrel for Fertility Control, *Med. J. Australia* 1:716-717 (May 12) 1962.
- Wisdom, C.: Investigator's Clinical Report, Dec. 23, 1963.
- Chinnatamby, S.: Clinical Trial of Oral Contraceptives, Annual Report, Family Planning Association of Ceylon, Colombo, 1963, pp. 23-26.
- Satterthwaite, A. P.: Investigator's Clinical Report, April 30, 1963.
- Satterthwaite, A. P.: Investigator's Clinical Report, May 10, 1963.
- Tyler, E. T.: Investigator's Clinical Report, March 31, 1963.
- García, C.-R., and Pincus, G.: Investigators' Clinical Report, April 30, 1963.
- Flowers, C. E.: Investigator's Clinical Report, June 27, 1963.
- Burket, R.: Investigator's Clinical Report, July 30, 1963.
- Andrews, W. C., and Andrews, M. C.: The Use of Progestins for Oral Contraception, *Southern Med. J.* 55:454-456 (May) 1962.
- Mears, E.: Clinical Trials of Oral Contraceptives, *Brit. Med. J.* 2:1179-1183 (Nov. 4) 1961.
- Mears, E.: A Comparative Study of Three Available Oral Contraceptives (Proceedings of the Society for the Study of Fertility, Annual Conference, June 27-30, 1962), *J. Reprod. Fertil.* 4:229-230 (Oct.) 1962.
- Pincus, G.: Suppression of Ovulation with Reference to Oral Contraceptives, in Gardiner-Hill, H. (editor): *Modern Trends in Endocrinology* 2nd series, London, Butterworth & Co. (Publishers), Ltd., 1961, pp. 231-245.
- Jackson, M. H.: Observations on the Use of Certain Orally Active Progestogens for the Control of Fertility in Women, *Proc. Roy. Soc. Med.* 54:16-19 (Nov.) 1961.
- Pullen, D.: "Conovid-E" as an Oral Contraceptive, *Brit. Med. J.* 2:1016-1019 (Oct. 20) 1962.
- Pincus, G.: Control of Reproduction in Mammals, in Wolstenholme, G. (editor): *Man and His Future*, Boston, Little, Brown & Co., 1963, pp. 79-90.
- García, C.-R., and Pincus, G.: Ovulation Inhibition by Progestin-Estrogen Combination, presented at the International Fertility Association Meeting in Brussels, Belgium, March 2-3, 1963, in press.
- Jackson, M. C. N.: Oral Contraception in Practice (The Sixth Oliver Bird Lecture), *J. Reprod. Fertil.* 6:153-173 (Aug.) 1963.
- Satterthwaite, A. P., and Gamble, C. J.: Conception Control with Norethynodrel: Progress Report of a Four-Year Field Study at Humacao, Puerto Rico, *J. Amer. Med. Wom. Ass.* 17:797-802 (Oct.) 1962.
- Satterthwaite, A. P.: Control of Ovulation with Norethynodrel; Progress Report of a Five-Year Field Study at Humacao, Puerto Rico, presented at the Fourth World Congress on Fertility in Rio de Janeiro, Aug. 8-15, 1962, in press.
- Gutmacher, A. F.: Oral Contraception, *Postgrad. Med.* 32:552-558 (Dec.) 1962.
- García, C.-R.: Symposium: Newer Developments in the Treatment of Menstrual Dysfunctions in Office Practice: Long-Term Experience, report presented at Jefferson Medical College, Philadelphia, April 27, 1963.
- Kistner, R. W.: Infertility with Endometriosis: A Plan of Therapy, *Fertil. Steril.* 13:237-245 (May-June) 1962.
- Tyler, E. T.: Oral Contraception, *J.A.M.A.* 175:225-226 (Jan. 21) 1961.
- Council on Drugs: New Drugs and Developments in Therapeutics: Norethynodrel with Mestranol (Enovid), *J.A.M.A.* 183:949-951 (March 16) 1963.
- Rock, J.: Population Growth (Editorial), *J.A.M.A.* 177:58-60 (July 8) 1961.
- Kistner, R. W.: The Use of Steroidal Substances in Endometriosis, *Clin. Pharmacol. Ther.* 1:525-537 (July-Aug.) 1960.
- Parkes, A. S.: Change and Control in Human Populations, *Lancet* 1:341-344 (Feb. 16) 1963.
- Flowers, C. E., in Goldfarb, A. F.: Ovulation Control, *Med. Sci.* 14:42-47 (Nov.) 1963.
- Kistner, R. W.: Steroid Compounds with Progestational Activity, *Postgrad. Med.* 35:225-232 (March) 1964.
- Grumbach, M. M.: Some Aspects of the Pathogenesis of Anomalies of Sex in Man, *Pacific Coast Fertility Society, Las Vegas, Nev.*, Nov. 12, 1960.
- Today's Drugs: Oral Contraceptives, *Brit. Med. J.* 2:550-551 (Aug. 31) 1963.
- Calderone, M. S.: Three Contraceptive Axioms, in Calderone, M. S. (editor): *Manual of Contraceptive Practice*, Baltimore, The Williams & Wilkins Company, 1964, pp. 151-153.